·2 Alnylam Third Quarter 2024 Financial Results October 31, 2024 1© 2024 Alnylam Pharmaceuticals, Inc. Agenda Welcome • Christine Lindenboom Chief Corporate Communications Officer Overview • Yvonne Greenstreet, MBChB, MBA Chief Executive Officer Commercial Highlights • Tolga Tanguler Chief Commercial Officer Alnylam Pipeline • Pushkal Garg, M.D. Chief Medical Officer Financial Summary and Upcoming Milestones • Jeff Poulton Chief Financial Officer Q&A Session 2 Alnylam Forward Looking Statements This present ...

Financial Data and Key Metrics Changes - In Q3 2024, Alnylam Pharmaceuticals achieved a 34% year-over-year growth in global net product revenue, generating $420 million across its four marketed products [6][38] - Net revenue from collaborations decreased by $370 million compared to the previous year, primarily due to the recognition of a $310 million upfront payment from Roche in Q3 2023 [39] - Royalty revenue for the quarter was $23 million, more than double the amount recognized in Q3 2023, driven by higher sales of Leqvio [40] - Gross margin on product sales improved to 80% from 75% in Q3 2023, attributed to lower costs associated with canceled manufacturing commitments in 2023 [41] Business Line Data and Key Metrics Changes - The TTR franchise generated $309 million in global net product revenues, reflecting a 34% increase year-over-year [11] - The rare franchise, including GIVLAARI and OXLUMO, delivered $111 million in combined net product sales, representing an 8% increase compared to Q2 2024 and 34% growth compared to Q3 2023 [18] Market Data and Key Metrics Changes - In the U.S., combined sales of ONPATTRO and AMVUTTRA increased by 37% year-over-year, driven by a 31% increase in demand for AMVUTTRA [13] - Internationally, the TTR franchise grew by 31% year-over-year, despite a 9% quarter-on-quarter decrease due to gross to net adjustments [14] Company Strategy and Development Direction - Alnylam aims to establish its TTR portfolio as a flagship franchise, similar to EYLEA for Regeneron, to drive long-term growth and investment in R&D [7] - The company is focused on advancing its pipeline, with plans to file proprietary INDs for 9 programs by the end of 2025, targeting various disease areas [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the Alnylam P5x25 goals by year-end 2025, emphasizing a strong pipeline of first and/or best-in-class product candidates [9] - The management highlighted the significant unmet need in ATTR cardiomyopathy and the potential for vutrisiran to address this market upon regulatory approval [15][16] Other Important Information - Alnylam announced the decision to stop clinical development of ALN-KHK, focusing resources on more promising programs [35] - The company ended Q3 2024 with cash, cash equivalents, and marketable securities of $2.8 billion, an increase from $2.4 billion at the end of 2023 [45] Q&A Session Summary Question: Can you elaborate on the work done to improve RNAi delivery to adipose tissue and muscle? - Management highlighted the well-tolerated nature of RNAi therapeutics and the sustained knockdown of disease-causing proteins, guided by human genetics for disease validation [49][50] Question: Regarding ALN-HTT02, what are the expectations for Phase 1 data? - Management expressed excitement about the Huntington's program, emphasizing the potential for sustained knockdown and unique efficacy due to targeting the exon 1 fragment of the gene [54][56] Question: How has the second silencer impacted the market for polyneuropathy? - Management noted a 37% year-over-year growth in the U.S. for polyneuropathy treatments, indicating strong demand despite new competition [60][61] Question: What are the payer discussions regarding potential label expansion? - Management discussed the importance of clinical outcomes in payer discussions and the company's patient access philosophy, which aims to minimize co-pay burdens for patients [71][73] Question: How does the company view the potential for a bolus of patients seeking new treatments? - Management indicated that the fast progression of ATTR cardiomyopathy will lead to early diagnosis and treatment, positioning AMVUTTRA as a first-line therapy [82][84] Question: What are the expectations for the acoramidis label and its relevance to Alnylam's launch? - Management expressed confidence in their data from HELIOS-B and indicated that they are closely monitoring the acoramidis label [87][88] Question: How should spending levels in SG&A be viewed relative to the upcoming launches? - Management indicated an expectation of double-digit growth in SG&A as they prepare for the launches in both the U.S. and Europe [93] Question: What are the company's thoughts on potential business development activities? - Management emphasized the focus on internal pipeline growth while remaining open to opportunities that enhance their platform [102]

Core Insights - Alnylam Pharmaceuticals reported a significant decline in revenue for Q3 2024, with total revenue of $500.92 million, down 33.3% year-over-year, and an EPS of -$0.50 compared to $1.15 a year ago [1] - The reported revenue fell short of the Zacks Consensus Estimate of $529.34 million, resulting in a surprise of -5.37% [1] Revenue Performance - Net Product Revenue for Oxlumo in the U.S. was $14.93 million, slightly below the average estimate of $15.73 million, but showed a year-over-year increase of 53.7% [3] - Net Product Revenue for Amvuttra in the U.S. reached $168.66 million, exceeding the average estimate of $153.83 million, with a year-over-year growth of 48.6% [3] - Net Product Revenue for Givlaari in the U.S. was $40.37 million, below the average estimate of $42.96 million, but still represented a 9.1% increase year-over-year [3] - Net Product Revenue for Onpattro in the U.S. was $16.21 million, below the average estimate of $18.23 million, reflecting a year-over-year decline of 25.9% [3] - Total net product revenues amounted to $420.15 million, surpassing the 10-analyst average estimate of $414.11 million, with a year-over-year increase of 34.2% [3] - Royalty revenue was reported at $23.39 million, exceeding the average estimate of $22.32 million, marking a significant year-over-year increase of 136.1% [3] - Net revenues from research collaborators were $57.39 million, falling short of the average estimate of $96.03 million [3] Stock Performance - Alnylam's shares have returned +3.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this RNA interference drug developer would post a loss of $0.74 per share when it actually produced earnings of $0.56, delivering a surprise of 175.68%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.01 par value per share ALNY The Nasdaq Stock Market LLC For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, with the aim of buying high and selling higher, leveraging established price movements for profitable trades [1]. Company Overview: Alnylam Pharmaceuticals (ALNY) - Alnylam Pharmaceuticals currently holds a Momentum Style Score of A, indicating strong momentum characteristics [1]. - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook based on historical performance metrics [2]. Performance Metrics - Over the past week, ALNY shares increased by 4.08%, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 2.24% [3]. - In the last month, ALNY's price change was 9.4%, significantly higher than the industry's 1.44% [3]. - Over the past quarter, ALNY shares have risen by 26.8%, and they have increased by 80.82% over the last year, compared to the S&P 500's gains of 5.5% and 40.28%, respectively [3]. Trading Volume - ALNY's average 20-day trading volume is 740,644 shares, which serves as a bullish indicator when combined with rising stock prices [3]. Earnings Outlook - In the last two months, one earnings estimate for ALNY has increased while one has decreased, leading to a consensus estimate improvement from -$0.83 to -$0.64 [4]. - For the next fiscal year, one estimate has moved upwards, while three have been revised downwards [4]. Conclusion - Given the strong performance metrics and positive earnings outlook, ALNY is positioned as a solid momentum pick with a Momentum Score of A and a Zacks Rank of 2 (Buy) [4].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Alnylam Pharmaceuticals is one of 1025 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks ...

Core Viewpoint - Alnylam Pharmaceuticals has submitted a Type II Variation to the European Medicines Agency for vutrisiran, aimed at treating ATTR amyloidosis with cardiomyopathy, which has positively impacted its stock price [1] Group 1: Company Developments - Vutrisiran is already marketed in the EU under the brand name Amvuttra for hereditary transthyretin-mediated amyloidosis [1] - The application for vutrisiran to treat ATTR-CM is backed by positive results from the HELIOS-B study, which met all primary and secondary endpoints with statistical significance [1][2] - Year-to-date, Alnylam's shares have increased by 57%, contrasting with a 1% decline in the industry [2] Group 2: Product Performance - Amvuttra generated sales of $425.4 million in the first half of 2024, reflecting an 82% year-over-year increase [3] - The growth in Amvuttra sales is attributed to new patient initiations and patients switching from Onpattro [3] - If approved, vutrisiran could become the new standard of care for ATTR-CM, significantly expanding the eligible patient population [4] Group 3: Other Products and Collaborations - Alnylam also markets Givlaari and Oxlumo for other conditions, contributing to its revenue [4] - The company collaborates with Novartis for Leqvio, which is approved for hypercholesterolemia treatment in the EU and the U.S. [5]

Alnylam Pharmaceuticals (ALNY) focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of experimental RNAi therapeutics is focused on three strategic therapeutic areas — genetic medicines, cardio-metabolic disease and hepatic infectious disease. Alnylam’s marketed portfolio of drugs comprises Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Onpattro (patisiran).Let’s delve deeper to discuss four reasons why adding Alnylam stock to your portfolio may prov ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Alnylam Pharmaceuticals (ALNY) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Alnylam Pharmaceuticals is one of 1026 individual stocks in the Medical sector. Colle ...